{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Participant 1 - T^1/2 alpha"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Participant 1 - T^1/2 beta"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Participant 2- T^1/2 alpha"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Participant 2- T^1/2 beta"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Venous whole blood samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. The half-lives of distribution (T\\^1/2 alpha) and elimination phases (T\\^1/2 beta) were to be listed and summarized using descriptive statistics.","groups":[{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"OG000","title":"Breast"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS). Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group. Due to the sample size in the dosimetry group (2 patients), summary statistics were not performed.","reportingStatus":"POSTED","timeFrame":"[68Ga]-NeoBOMB1 PET imaging acquired at Day 1","title":"Dosimetry Group: Half-life of [68Ga]-NeoBOMB1 in Blood (T^1/2)","type":"SECONDARY","unitOfMeasure":"min"}